More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer

Haen, Sebastian P.; Pereira, Philippe L.; Salih, Helmut R.; Rammensee, Hans‐Georg; Gouttefangeas, Cécile

doi:10.1155/2011/160250

Cited by 198 publications

(159 citation statements)

References 138 publications

(218 reference statements)

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Recent fascinating discoveries are revealing new insights in the mechanisms of action of HIFU which go beyond the mere local generation of hyperthermia for tumor ablation (80).…”

Section: Discussionmentioning

confidence: 99%

High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system—current state of the art and future perspectives

Diana¹,

Schiraldi²,

Liu³

et al. 2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

Background: High intensity focused ultrasound (HIFU) is emerging as a valid minimally-invasive imageguided treatment of malignancies. We aimed to review to current state of the art of HIFU therapy applied to the digestive system and discuss some promising avenues of the technology.Methods: Pertinent studies were identified through PubMed and Embase search engines using the following keywords, combined in different ways: HIFU, esophagus, stomach, liver, pancreas, gallbladder, colon, rectum, and cancer. Experimental proof of the concept of endoluminal HIFU mucosa/submucosa ablation using a custom-made transducer has been obtained in vivo in the porcine model. Results:Forty-four studies reported on the clinical use of HIFU to treat liver lesions, while 19 series were found on HIFU treatment of pancreatic cancers and four studies included patients suffering from both liver and pancreatic cancers, reporting on a total of 1,682 and 823 cases for liver and pancreas, respectively. Only very limited comparative prospective studies have been reported. Conclusions:Digestive system clinical applications of HIFU are limited to pancreatic and liver cancer. It is safe and well tolerated. The exact place in the hepatocellular carcinoma (HCC) management algorithm remains to be defined. HIFU seems to add clear survival advantages over trans arterial chemo embolization (TACE) alone and similar results when compared to radio frequency (RF). For pancreatic cancer, HIFU achieves consistent cancer-related pain relief. Further research is warranted to improve targeting accuracy and efficacy monitoring. Furthermore, additional work is required to transfer this technology on appealing treatments such as endoscopic HIFU-based therapies.Keywords: High intensity focused ultrasound (HIFU); liver cancer; pancreatic cancer; miniature HIFU delivery system; endoluminal applications of HIFU; mucosa and submucosal ablations using HIFU

show abstract

“…Recent fascinating discoveries are revealing new insights in the mechanisms of action of HIFU which go beyond the mere local generation of hyperthermia for tumor ablation (80).…”

Section: Discussionmentioning

confidence: 99%

High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system—current state of the art and future perspectives

Diana¹,

Schiraldi²,

Liu³

et al. 2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

show abstract

“…This being an observational and not randomized study, the interpretation of these data can be not univocal. Immune modulation is the other strong motivation to propose RFA [17] as up front treatment to patients with LAC: an increasing number of studies have been published regarding the role of thermal ablation in stimulating and modulating the immune system and the immune response against the tumor [18][19][20][21]. Dromi et al [22] demonstrates in animals an increase of dendritic cell infiltration, which are the most powerful antigen presenting cells, following the ablation: subtotal RFA treatment results in systemic antitumor T cell immune responses and tumor regression.…”

Section: Discussionmentioning

confidence: 99%

Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center

Frigerio

Girelli

Giardino

et al. 2013

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Background Neo-adjuvant chemotherapy (CHT) has gained increasing importance in resectable and borderline resectable pancreatic cancer leading to a better performing surgery when we look at negative resection margins and selection of patients with less aggressive disease. We apply this principle to patients with Stage III (LAC) pancreatic cancer undergoing RFA and try to select patients who may benefit from a local treatment. Methods All patients affected by LAC were treated with RFA for a stable disease after a short CHT. Postoperative morbidity and mortality were evaluated together with overall survival (OS) and disease specific survival (DSS). Results We consecutively treated 57 patients affected by LAC. Median duration of CHT before RFA was 5 months. The postoperative mortality rate was zero. Overall morbidity was 14 % with RFA-related morbidity of 3.5 %. The OS and DSS were 19 months and when compared to a similar population who received RFA as up front treatment, there was no difference. Conclusions Our results do not support the adoption of a short CHT as a way to identify patients to treat with RFA with the most benefit. Based on this and by knowing the role of immune modulation after RFA and its specific involvement in pancreatic carcinoma, we can propose RFA as upfront treatment.

show abstract

“…This therapeutic approach is based on the local cooling (cryoablation) or heating (radiofrequency (RF), high-intensity focused ultrasound (HIFU) or photothermal ablation) of cancer tissue. For all these different techniques, immunogenic cell death and associated release of DAMPs such as heat shock proteins (HSP) and HMGB1, as well as increased immunostimulatory cytokine secretion and infiltration of APCs into the ablated regions, was reported [145]. Here too, NPs can be designed aiming to improve the thermal effects and simultaneously boost the induced antitumor immunity.…”

Section: Thermo-immunotherapymentioning

confidence: 99%

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

et al. 2014

View full text Add to dashboard Cite

Over the years research in the field of cancer immunotherapy has flourished, bringing about crucial breakthroughs, but at the same time revealing new and important pathways of immune suppression that put a break on the success of cancer immunotherapy. This review focuses on how nano-and micromaterials can be used to induce antitumor immune responses and what their role in overcoming immune suppression could be. It is now beyond question that this requires elegantly designed particles that can reach their target cells, deliver antigenic cargo and most importantly immune stimulants in order to provoke and sustain antitumor immunity.3

show abstract

More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer

Cited by 198 publications

References 138 publications

High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system—current state of the art and future perspectives

High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system—current state of the art and future perspectives

Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

Contact Info

Product

Resources

About